Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.

[1]  J. Coresh,et al.  A Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex With Acute Kidney Injury. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  J. Lewis,et al.  Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View , 2015 .

[3]  J. Lewis,et al.  Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[4]  B. Najafian.  Microalbuminuria: target for renoprotective therapy PRO. , 2015, Kidney international.

[5]  D. de Zeeuw,et al.  Microalbuminuria: target for renoprotective therapy PRO. , 2014, Kidney international.

[6]  H. Heerspink,et al.  The effect of RAAS blockade on the progression of diabetic nephropathy , 2014, Nature Reviews Nephrology.

[7]  H. Heerspink,et al.  The effect of RAAS blockade on the progression of diabetic nephropathy , 2014, Nature Reviews Nephrology.

[8]  A. Davenport,et al.  Reading between the (guide)lines--the KDIGO practice guideline on acute kidney injury in the individual patient. , 2014, Kidney international.

[9]  P. Peduzzi,et al.  Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.

[10]  H. Heerspink,et al.  Cardiovascular endocrinology: Dual RAAS blockade has dual effects on outcome , 2013, Nature Reviews Endocrinology.

[11]  D. de Zeeuw,et al.  Dual RAAS blockade has dual effects on outcome. , 2013, Nature reviews. Endocrinology.

[12]  Nish Chaturvedi,et al.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.

[13]  Merlin C. Thomas,et al.  An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. , 2011, Kidney international.

[14]  L. Ruilope,et al.  Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. , 2011, The New England journal of medicine.

[15]  Mark Woodward,et al.  Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. , 2009, Journal of the American Society of Nephrology : JASN.

[16]  H. Parving,et al.  Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria , 2009, Diabetes Care.

[17]  S. Solomon,et al.  Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  M. Woodward,et al.  Lowering blood pressure reduces renal events in type 2 diabetes. , 2009, Journal of the American Society of Nephrology : JASN.

[19]  R. Garrick.  Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy , 2009 .

[20]  R. Kunz,et al.  Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the ReninAngiotensin System on Proteinuria in Renal Disease , 2008, Annals of Internal Medicine.

[21]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[22]  B. Brenner,et al.  Preventing microalbuminuria in type 2 diabetes. , 2005, The New England journal of medicine.

[23]  Zhongxin Zhang,et al.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. , 2004, Kidney international.

[24]  M. Perazella,et al.  The Renin‐Angiotensin‐Aldosterone System: Cardiorenal Effects and Implications for Renal and Cardiovascular Disease States , 2003, The American journal of the medical sciences.

[25]  G. Remuzzi,et al.  Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. , 2003, Kidney international.

[26]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[27]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[28]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[29]  C. Schmid,et al.  Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. , 2001, Kidney international.

[30]  C. Schmid,et al.  Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. , 2001, Annals of internal medicine.

[31]  D. de Zeeuw,et al.  A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. , 1997, Kidney international.

[32]  L. Skeggs,et al.  THE PREPARATION, PURIFICATION, AND AMINO ACID SEQUENCE OF A POLYPEPTIDE RENIN SUBSTRATE , 1957, The Journal of experimental medicine.